Calcium phosphate (CaP) ceramics are widely used in bone regenerative medicine for their osteoconductive properties. Osteogrow-C is a novel device that comprises recombinant human bone morphogenetic protein 6 (rhBMP6) in autologous blood coagulum, utilizing ceramics as a compression-resistant matrix. This study evaluated how CaP granule size and composition affect bone formation and implant integrity in 2 relevant animal models: the rat subcutaneous model and rabbit posterolateral lumbar fusion (PLF) model, over 1 year. The implants in the rat model had varying granule size ranges (74 to 420 μm, 500 to 1,700 μm, 2,360 to 4,000 μm) and compositions β-tricalcium phosphate (β-TCP), hydroxyapatite (HA), and biphasic ceramics (TCP/HA 80/20). Micro-computed tomography (CT) and histology showed that Osteogrow-C induced bone formation on all ceramic scaffolds, with smaller granules resulting in higher bone volume and density, regardless of composition. TCP granules were most resorbed, but residual ceramics persisted in all groups. Based on these findings, Osteogrow-C, containing small granules with different compositions (TCP, HA, TCP/HA 80/20, and TCP/HA 40/60), was further tested in the clinically relevant rabbit PLF model and induced fusion of transverse processes. Importantly, ceramics were more resorbed in the rabbit PLF model, with TCP and TCP/HA 80/20 ceramics showing the highest resorption rate, while HA remained intact. Osteogrow-C containing HA showed increased bone volume; however, biomechanical strength and thicker cortical bone were achieved with TCP and biphasic calcium phosphate (BCP). Finally, in the rat model, bone volume was primarily dependent on granule size, with smaller granules promoting greater bone formation and density. Conversely, in the PLF model, the composition played a more important role-affecting ceramic resorption, bone volume, and biomechanical properties.
Štoković et al. (Thu,) studied this question.